ReviewKidney international reports2026

Moving Mendelian Randomization From Traditional Risk Factors to Molecular Targets for Drug Development and Clinical Trials in Nephrology.

Abigail J Berube et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.